{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:28:52Z","timestamp":1755221332405,"version":"3.43.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06417-8","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T23:57:57Z","timestamp":1748044677000},"page":"3881-3887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subclonal emergence of polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Violaine","family":"Tran Quang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules","family":"Cretin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Loyaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilel","family":"Ben Jedidia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihem","family":"Tarfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Gricourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Barathon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine","family":"Joy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascaline","family":"Etancelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orianne","family":"Wagner-Ballon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pautas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Sloma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"6417_CR1","doi-asserted-by":"publisher","first-page":"1329298","DOI":"10.3389\/fonc.2023.1329298","volume":"13","author":"M Zanelli","year":"2024","unstructured":"Zanelli M, Bisagni A, Sanguedolce F et al (2024) Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination. Front Oncol 13:1329298. https:\/\/doi.org\/10.3389\/fonc.2023.1329298","journal-title":"Front Oncol"},{"key":"6417_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jmoldx.2022.07.004","volume":"24","author":"G Gricourt","year":"2022","unstructured":"Gricourt G, Tran Quang V, Cayuela J-M et al (2022) Fusion gene detection and quantification by asymmetric capture sequencing (aCAP-Seq). J Mol Diagn 24:1113\u20131127. https:\/\/doi.org\/10.1016\/j.jmoldx.2022.07.004","journal-title":"J Mol Diagn"},{"key":"6417_CR3","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","volume":"23","author":"JI Hsu","year":"2018","unstructured":"Hsu JI, Dayaram T, Tovy A et al (2018) PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell 23:700\u2013713e6. https:\/\/doi.org\/10.1016\/j.stem.2018.10.004","journal-title":"Cell Stem Cell"},{"key":"6417_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","volume":"132","author":"JD Kahn","year":"2018","unstructured":"Kahn JD, Miller PG, Silver AJ et al (2018) Myeloid neoplasia: PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D Inhibition in hematopoietic cells. Blood 132:1095. https:\/\/doi.org\/10.1182\/blood-2018-05-850339","journal-title":"Blood"},{"key":"6417_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/bloodadvances.2018024216","volume":"3","author":"H Awada","year":"2019","unstructured":"Awada H, Nagata Y, Goyal A et al (2019) Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Adv 3:339\u2013349. https:\/\/doi.org\/10.1182\/bloodadvances.2018024216","journal-title":"Blood Adv"},{"key":"6417_CR6","doi-asserted-by":"publisher","unstructured":"Garcia-Gisbert N, Arenillas L, Roman-Bravo D et al (2022) Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia. Leukemia 1\u20135. https:\/\/doi.org\/10.1038\/s41375-022-01733-8","DOI":"10.1038\/s41375-022-01733-8"},{"key":"6417_CR7","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3324\/haematol.2022.282528","volume":"108","author":"VT Quang","year":"2023","unstructured":"Quang VT, Podvin B, Desterke C et al (2023) TET2 mutational status affects myelodysplastic syndrome evolution to chronic myelomonocytic leukemia. Haematologica 108:3135\u20133141. https:\/\/doi.org\/10.3324\/haematol.2022.282528","journal-title":"Haematologica"},{"key":"6417_CR8","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/BLOOD-2015-01-620781","volume":"125","author":"D Selimoglu-Buet","year":"2015","unstructured":"Selimoglu-Buet D, Wagner-Ballon O, Saada V et al (2015) Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 125:3618. https:\/\/doi.org\/10.1182\/BLOOD-2015-01-620781","journal-title":"Blood"},{"key":"6417_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1002028","journal-title":"N Engl J Med"},{"key":"6417_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia Vera. N Engl J Med 372:426\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"key":"6417_CR11","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1158\/1078-0432.CCR-21-0935","volume":"27","author":"AM Hunter","year":"2021","unstructured":"Hunter AM, Newman H, Dezern AE et al (2021) Integrated human and murine clinical study establishes clinical efficacy of ruxolitinib in chronic myelomonocytic leukemia. Clin Cancer Res 27:6095\u20136105. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0935","journal-title":"Clin Cancer Res"},{"key":"6417_CR12","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","volume":"22","author":"E Padron","year":"2016","unstructured":"Padron E, Dezern A, Andrade-Campos M et al (2016) A Multi-Institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML). Clin Cancer Res 22:3746\u20133754. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2781","journal-title":"Clin Cancer Res"},{"key":"6417_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","volume":"11","author":"E Mylonas","year":"2020","unstructured":"Mylonas E, Yoshida K, Frick M et al (2020) Single-cell analysis based dissection of clonality in myelofibrosis. Nat Commun 11:73. https:\/\/doi.org\/10.1038\/s41467-019-13892-x","journal-title":"Nat Commun"},{"key":"6417_CR14","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1038\/s41375-023-02027-3","volume":"37","author":"JM O\u2019Sullivan","year":"2023","unstructured":"O\u2019Sullivan JM, Taylor J, Gerds A et al (2023) RAS-pathway mutations are common in patients with ruxolitinib refractory\/intolerant myelofibrosis: molecular analysis of the PAC203 cohort. Leukemia 37:2497\u20132501. https:\/\/doi.org\/10.1038\/s41375-023-02027-3","journal-title":"Leukemia"},{"key":"6417_CR15","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","volume":"132","author":"S Branford","year":"2018","unstructured":"Branford S, Wang P, Yeung DT et al (2018) Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood 132:948\u2013961. https:\/\/doi.org\/10.1182\/blood-2018-02-832253","journal-title":"Blood"},{"key":"6417_CR16","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.3324\/haematol.2022.282184","volume":"108","author":"N Shanmuganathan","year":"2023","unstructured":"Shanmuganathan N, Wadham C, Shahrin N et al (2023) Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica 108:2380\u20132395. https:\/\/doi.org\/10.3324\/haematol.2022.282184","journal-title":"Haematologica"},{"key":"6417_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","volume":"129","author":"T Kim","year":"2017","unstructured":"Kim T, Tyndel MS, Kim HJ et al (2017) Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood 129:38\u201347. https:\/\/doi.org\/10.1182\/blood-2016-04-708560","journal-title":"Blood"},{"key":"6417_CR18","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1182\/blood-2023-186271","volume":"142","author":"H Guerineau","year":"2023","unstructured":"Guerineau H, Cayuela J-M, Dulucq S et al (2023) Mutation of epigenetic regulators at diagnosis is an independent predictor of tyrosine kinase inhibitor treatment failure: A report from the residiag study. Blood 142:4540. https:\/\/doi.org\/10.1182\/blood-2023-186271","journal-title":"Blood"},{"key":"6417_CR19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","volume":"124","author":"P Gallipoli","year":"2014","unstructured":"Gallipoli P, Cook A, Rhodes S et al (2014) JAK2\/STAT5 Inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34\u2009+\u2009cells in vitro and in vivo. Blood 124:1492\u20131501. https:\/\/doi.org\/10.1182\/blood-2013-12-545640","journal-title":"Blood"},{"key":"6417_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.exphem.2017.05.007","volume":"53","author":"I Sloma","year":"2017","unstructured":"Sloma I, Mitjavila-Garcia MT, Feraud O et al (2017) Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia. Exp Hematol 53:48\u201358. https:\/\/doi.org\/10.1016\/j.exphem.2017.05.007","journal-title":"Exp Hematol"},{"key":"6417_CR21","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"EA Nelson","year":"2011","unstructured":"Nelson EA, Walker SR, Weisberg E et al (2011) The STAT5 inhibitor Pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117:3421\u20133429. https:\/\/doi.org\/10.1182\/blood-2009-11-255232","journal-title":"Blood"},{"key":"6417_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.leukres.2013.11.006","volume":"38","author":"C Quintarelli","year":"2014","unstructured":"Quintarelli C, De Angelis B, Errichiello S et al (2014) Selective strong synergism of ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. Leuk Res 38:236\u2013242. https:\/\/doi.org\/10.1016\/j.leukres.2013.11.006","journal-title":"Leuk Res"},{"key":"6417_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","volume":"74","author":"K Sweet","year":"2018","unstructured":"Sweet K, Hazlehurst L, Sahakian E et al (2018) A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res 74:89\u201396. https:\/\/doi.org\/10.1016\/j.leukres.2018.10.002","journal-title":"Leuk Res"},{"key":"6417_CR24","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.20.02864","volume":"39","author":"J Mascarenhas","year":"2021","unstructured":"Mascarenhas J, Komrokji RS, Palandri F et al (2021) Randomized, Single-Blind, multicenter phase II study of two doses of Imetelstat in relapsed or refractory myelofibrosis. JCO 39:2881\u20132892. https:\/\/doi.org\/10.1200\/JCO.20.02864","journal-title":"JCO"},{"key":"6417_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","volume":"403","author":"U Platzbecker","year":"2024","unstructured":"Platzbecker U, Santini V, Fenaux P et al (2024) Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 403:249\u2013260. https:\/\/doi.org\/10.1016\/S0140-6736(23)01724-5","journal-title":"Lancet"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06417-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T16:02:46Z","timestamp":1754668966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06417-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6417"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06417-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report complied with French regulations and was approved by the Henri Mondor. Institutional Review Board (No. 00011558). The study methodologies conformed to the standards set by the Declaration of Helsinki. All patient data were anonymized and de-identified before analysis, and informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed with the content of the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IS is a speaker for Novartis and Incyte. IS is a co-inventor of a know-how licensed by AP-HP to Agilent Technologies. OWB has a patent issued relevant to this work. Other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}